ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2022 American Transplant Congress
    • 2021 American Transplant Congress
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2021 Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Search

Potential Benefits of Y-90 Radiation Microspheres for Bridging Liver Candidates with Hepatocellular Carcinoma to Liver Transplant

S. Pelletier1, J. Durden2, S. Shan2, P. Vargas3, N. Goldaracena1

1University of Virginia Health System, Charlottesville, VA, 2School of Medicine, University of Virginia Health System, Charlottesville, VA, 3Department of Surgery, University of Virginia Health System, Charlottesville, VA

Meeting: 2020 American Transplant Congress

Abstract number: 148

Keywords: Hepatocellular carcinoma

Session Information

Session Name: Liver: Hepatocellular Carcinoma and Other Malignancies I

Session Type: Oral Abstract Session

Date: Saturday, May 30, 2020

Session Time: 3:15pm-4:45pm

 Presentation Time: 4:03pm-4:15pm

Location: Virtual

*Purpose: In October 2015, the UNOS policy for hepatocellular carcinoma (HCC) exception scores was changed to modify the maximum exception value and prolong the time until the score was increased (6-month waiting time). This increases the need to bridge HCC liver candidates with locoregional therapy (LRT). Around the same time, utilization of Y-90 radiation microspheres (Y-90) has become more popular but limited data exists to support its use for waiting list survival and successful bridge to transplant.

*Methods: Using OPTN data, all HCC liver transplant candidates listed and who received an exception after the policy (Oct 5, 2015) were included in the study. Recipient, OPO, Region, and Center demographics were analyzed for univariate and multivariate risk factors for waiting list mortality and successful bridging to transplant. Univariate analysis was performed using chi square, t-test, and Kaplan Meir curves and Cox Proportional Hazard models were used for multivariate analysis.

*Results: During the study period (Oct 5, 2015 to Jun 10, 2019), 1,538 (17.0%) were treated with Y-90 either before or during listing of a total of 9,031 candidates. 15.3% of candidates treated with Y-90 died during the observation period compared to 16.26% (p=ns) who received other LRT’s. Y-90 candidates were similar with respect to age, MELD, gender, blood type, but were more likely to have private insurance, higher functional status, less comorbidities, and had a shorter waiting time. Having received Y-90 while on the transplant waiting list was not an independent predictor of mortality (HR 1.10, p=0.28). A lower proportion of candidates receiving Y-90 (46.8%; p=0.007) were bridged to transplant compared to TACE (53.4%, n=3,381), external radiation (51.1%, n=143), or thermal ablation (50.4%, n=1,783). When controlling for confounding variables with multivariate analysis, Y-90 did not significantly impact the likelihood for transplant (HR 0.71, CI 0.42-1.22, p=0.21).

*Conclusions: With changes in UNOS policy that have capped MELD exception scores and mandated a waiting time until receiving exception points, more effective LRT is needed to bridge HCC candidates to liver transplant. While Y-90 utilization is increasing, it is associated with a decreased likelihood to receive a liver transplant but is not an independent risk factor for receiving a transplant or waiting list mortality.

  • Tweet
  • Email
  • Print

To cite this abstract in AMA style:

Pelletier S, Durden J, Shan S, Vargas P, Goldaracena N. Potential Benefits of Y-90 Radiation Microspheres for Bridging Liver Candidates with Hepatocellular Carcinoma to Liver Transplant [abstract]. Am J Transplant. 2020; 20 (suppl 3). https://atcmeetingabstracts.com/abstract/potential-benefits-of-y-90-radiation-microspheres-for-bridging-liver-candidates-with-hepatocellular-carcinoma-to-liver-transplant/. Accessed May 11, 2025.

« Back to 2020 American Transplant Congress

Visit Our Partner Sites

American Transplant Congress (ATC)

Visit the official site for the American Transplant Congress »

American Journal of Transplantation

The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

American Society of Transplantation (AST)

An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

American Society of Transplant Surgeons (ASTS)

The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

Copyright © 2013-2025 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

Privacy Policy | Terms of Use | Cookie Preferences